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Abstract 
Background: Thromboembolism has been reported as a consequence of severe COVID-19. Although warfarin is a 
commonly used anticoagulant, it acts by antagonising vitamin K, which is low in patients with severe COVID-19. To 
date, the clinical evidence on the impact of regular use of warfarin on COVID-19-related thromboembolism is lacking.
Methods: On behalf of NHS England, we conducted a population-based cohort study investigating the association 
between warfarin and COVID-19 outcomes compared with direct oral anticoagulants (DOACs). We used the Open-
SAFELY platform to analyse primary care data and pseudonymously linked SARS-CoV-2 antigen testing data, hospital 
admissions and death records from England. We used Cox regression to estimate hazard ratios (HRs) for COVID-19-re-
lated outcomes comparing warfarin with DOACs in people with non-valvular atrial fibrillation. We also conducted 
negative control outcome analyses (being tested for SARS-CoV-2 and non-COVID-19 death) to assess the potential 
impact of confounding.
Results: A total of 92,339 warfarin users and 280,407 DOAC users were included. We observed a lower risk of all 
outcomes associated with warfarin versus DOACs [testing positive for SARS-CoV-2, HR 0.73 (95% CI 0.68–0.79); COVID-
19-related hospital admission, HR 0.75 (95% CI 0.68–0.83); COVID-19-related deaths, HR 0.74 (95% CI 0.66–0.83)]. A 
lower risk of negative control outcomes associated with warfarin versus DOACs was also observed [being tested for 
SARS-CoV-2, HR 0.80 (95% CI 0.79–0.81); non-COVID-19 deaths, HR 0.79 (95% CI 0.76–0.83)].
Conclusions: Overall, this study shows no evidence of harmful effects of warfarin on severe COVID-19 disease.
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Background
People with severe COVID-19 disease have a high risk 
of thromboembolism [1, 2], and it is also known that 
lower levels of vitamin K could lead to pro-throm-
botic conditions [3]. This might also lead to poorer 
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outcomes among patients with COVID-19 treated 
with warfarin, which works by antagonising vitamin K. 
Unlike warfarin, the mechanism of action of direct oral 
anticoagulants (DOACs) is independent of vitamin K.
To date, there is limited evidence comparing out-
comes from COVID-19 between patients treated with 
warfarin and those treated with DOACs. Current stud-
ies comparing the outcomes from COVID-19 between 
patients treated with warfarin and/or DOACs with 
non-anticoagulant users [4–7] limit the understand-
ing of risks and benefits of prescribing different types 
of oral anticoagulants specifically in the context of the 
COVID-19 pandemic.
We therefore conducted a population-based cohort 
study to investigate the association between routinely 
prescribed warfarin and COVID-19-related outcomes, 
in comparison with those treated with DOACs. To 
minimise confounding by indication, we compared 




We conducted a population-based cohort study 
between 1 March 2020 and 28 September 2020.
Data source
Primary care records managed by the software pro-
vider TPP were linked to SARS-CoV-2 antigen testing 
data from the Second Generation Surveillance System, 
COVID-19-related hospital admissions from the second-
ary uses service, and Office for National Statistics death 
data through OpenSAFELY, a data analytics platform cre-
ated by our team on behalf of NHS England [8]. The data 
set analysed within OpenSAFELY is based on 24 million 
people currently registered with primary care practices 
using TPP SystmOne software, representing 40% of the 
English population. It includes pseudonymised data such 
as coded diagnoses, prescribed medications and physi-
ological parameters.
Study populations and exposure
We first identified all patients with a diagnosis of AF 
on or before study start (1 March 2020) (Fig. 1). People 
with missing data for sex, Index of Multiple Depriva-
tion, < 1 year of primary care records, or aged < 18 or > 110 
and prescribed injectable anticoagulants 4 months before 
study start date were excluded. In addition, people with a 
record of mitral stenosis or prosthetic mechanical valves, 
chronic kidney disease stage V (estimated glomerular 
filtration rate < 15  mL/min or on dialysis), or antiphos-
pholipid antibody syndrome before study start were also 
excluded in this study because DOACs are not recom-
mended for use in these patient groups.
Fig. 1 Study diagram
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We defined participants as DOAC users if they were 
prescribed a DOAC as their latest OAC prescription in 
the 4 months before study start. The comparison group 
was people who were prescribed warfarin as the lat-
est OAC prescription in the 4 months before study start 
date. If both warfarin and DOACs were prescribed on 
the same day as the latest prescription (n = 32), we clas-
sified them as warfarin users as a conservative estimate 
because warfarin is hypothesised to have a harmful effect 
on severe COVID-19 compared with DOACs.
Outcomes and follow‑up
The outcomes were (1) testing positive for SARS-
CoV-2, (2) COVID-19-related hospital admission, and 
(3) COVID-19-related death (defined as the presence of 
ICD-10 codes U071 (confirmed COVID-19) and U072 
(suspected COVID-19) anywhere on the death certifi-
cate). Testing outcomes were obtained from the UK’s 
Pillar 1 (NHS and Public Health England laboratories) 
and Pillar 2 (commercial partners) testing strategies and 
included results from polymerase chain reaction swab 
tests used to identify symptomatic individuals [9]. As 
pre-specified analyses, we also conducted negative con-
trol outcome analyses to examine the presence of residual 
confounding between warfarin and DOAC users. First, 
we anticipated that, within our population of people with 
non-valvular AF, there were unlikely to be marked differ-
ences in the likelihood of being tested for SARS-CoV-2 
infection in relation to drug treatment with warfarin or 
DOAC. Therefore, we included being tested for SARS-
CoV-2 as a negative control outcome to test our assump-
tion. Second, we also included non-COVID-19 death, 
as differences in this outcome between DOAC and war-
farin users could imply that differences in health char-
acteristics had not been successfully controlled for. We 
conducted additional post hoc analyses to include cause-
specific deaths as outcomes (i.e. death due to myocardial 
infarction, ischaemic stroke, venous thromboembolism, 
gastrointestinal bleeding and intracranial bleeding) to aid 
the interpretation of our results.
Follow-up for each cohort began on 1 March 2020 and 
ended at the latest of the outcome of interest in each 
analysis, deregistration from the TPP practice, death or 
study end date (28 September 2020) (Fig. 1).
Covariates
Covariates were pre-specified, identified from a directed 
acyclic graph (DAG) approach (Additional file  1: Figure 
S1), including age, sex, obesity, smoking status, hyper-
tension, heart failure, myocardial infarction, peripheral 
arterial disease, stroke/transient ischemic attack, venous 
thromboembolism, diabetes, flu vaccination, current 
antiplatelet use, current oestrogen and oestrogen-like 
therapy use, Index of Multiple Deprivation and care 
home residence. We identified covariates that are both 
associated with the exposure and the risk of severe 
COVID-19 outcomes either directly [8], or via venous 
thromboembolism [10, 11]. All codelists for identifying 
exposures, covariates and outcomes are openly shared at 
https:// codel ists. opens afely. org/ for inspection and reuse.
Statistical methods
Baseline characteristics in each study were summarised 
using descriptive statistics, stratified by exposure sta-
tus. We present adjusted cumulative incidence/mortal-
ity curves using the Royston–Parmar model (Additional 
file 1: Figure S2). We estimated hazard ratios (HRs) with 
95% confidence intervals (CIs) using Cox regression with 
time since cohort entry as the underlying timescale. We 
accounted for competing risk by modelling the cause-
specific hazard (i.e. censoring other deaths for COVID-
19 death analysis and censoring any death for other 
outcomes analysis). We used graphical methods and tests 
based on Schoenfeld residuals to explore violations of the 
proportional hazards assumption.
We performed unadjusted models, models adjusted for 
age (using restricted cubic splines) and sex, and DAG-
adjusted models (stratified by general practice).
Quantitative bias analysis
We considered the possibility that if warfarin users had 
worse baseline health status they might act to lower their 
risk of SARS-CoV-2 infection through more risk-averse 
health behaviours (e.g. wearing face masks, avoiding close 
proximity to others) than DOAC users. Given that health 
behaviour is not captured in medical records, we con-
ducted quantitative bias analyses to assess the sensitivity 
of our results to this potential unmeasured confounder.
We calculated the minimum strength of association 
required between an unmeasured confounder and one 
of exposure or outcome to move from the observed HR 
to a null bias-adjusted HR (aHR) (i.e. the E value) [12]. 
We also calculated the minimum strength of association 
required between unmeasured confounder and both of 
exposure and outcome to move from the observed HR 
to a null bias-aHR (i.e. the Cornfield condition) [12]. 
Furthermore, we calculated the minimum strength of 
association required to move from the observed protec-
tive associations to a bias-aHR of 1.2 because we hypoth-
esised a harmful effect of warfarin in COVID-19-related 
outcomes.
Sensitivity analyses
Table 1 shows the list of other sensitivity analyses.
Data management was performed using Python 3.8 
and SQL, with analysis carried out using Stata 16.1. All 
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study analyses were pre-planned unless otherwise stated. 
All code for data management and analyses in addition 
to the pre-specified protocol (https:// github. com/ opens 
afely/ antic oagul ants- resea rch/ blob/ master/ proto col/ 
Proto col_% 20Ant icoag% 20Ope nSAFE LY_ v3. docx) are 
archived at: https:// github. com/ opens afely/ antic oagul 
ants- resea rch.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or writ-
ing of the report. AJW, CEM, SB, WH, CB, JC, LS and 
BG had access to the raw data. The corresponding author 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Figure  2 shows the flow chart of inclusion of people to 
develop the study cohort.
We included 92,339 warfarin users and 280,407 DOAC 
users (Table  2). Median age was 79  years (IQR, 73–85) 
among warfarin users and 78 years (IQR, 71–84) among 
DOAC users. A higher proportion of men were warfarin 
users (60.6%) than DOAC users (56.2%).
Current warfarin users were more likely to be obese, 
former smokers and have comorbidities than DOAC 
users, and had a greater number of primary care consul-
tations and previous vaccinations. Current warfarin users 
were less likely to have a recent prescription for antiplate-
lets than DOAC users.
Figure S2 presents time to each outcome in adjusted 
cumulative incidence plots. We observed a lower risk for 
all outcomes associated with current use of warfarin ver-
sus current use of DOACs (Fig.  3 and Additional file  1: 
Table S1). A lower risk of testing positive for SARS-CoV-2 
[unadjusted HR 0.69 (95% CI 0.64–0.74); DAG-aHR 0.73 
(95% CI 0.68–0.79)], COVID-19-related hospital admis-
sion [unadjusted HR 0.77 (95% CI 0.70–0.85); DAG-aHR 
0.75 (95% CI 0.68–0.83)], and COVID-19-related deaths 
[unadjusted HR 0.71 (95% CI 0.64–0.79); DAG-aHR 0.74 
(95% CI 0.66–0.83)] were observed comparing current 
use of warfarin with current use of DOACs.
For the negative control outcome of being tested for 
SARS-CoV-2, the unadjusted HR for current use of war-
farin was 0.77 (95% CI 0.76–0.79), with a DAG-aHR of 
0.80 (95% CI 0.79–0.81) versus current use of DOACs. 
For non-COVID-19 deaths, the unadjusted HR was 0.81 
(95% CI 0.78–0.84) with DAG-aHR of 0.79 (95% CI 0.76–
0.83) comparing current use of warfarin with current use 
of DOACs.
In the post hoc analyses investigating cause-specific 
deaths, no differences in risk of each specific outcome 
were observed, although we had limited power for this 
analysis (Additional file  1: Table  S1). The results of all 
other sensitivity analyses were broadly similar to those of 
the main analyses (Additional file 1: Tables S2–S6).
Quantitative bias analysis
To potentially fully explain the observed non-null 
inverse associations, either DOAC use would need to 
Table 1 List of sensitivity analyses
Sensitivity analysis Justification
1. In addition to the covariates identified by DAG, we included other 
covariates based on prior evidence of likely confounders such as chronic 
obstructive pulmonary disease, other respiratory diseases, cancer, immu-
nosuppression, chronic kidney disease, general practice attendance rate 
in the year prior to cohort entry, and A&E attendance rate in the year prior 
to cohort entry in the fully adjusted models (stratified by general practice)
To test the robustness of the covariate selection
2. Additionally adjusted for ethnicity in DAG and fully adjusted models. In 
the fully adjusted models, additional covariates included chronic obstruc-
tive pulmonary disease, other respiratory diseases (not including asthma), 
cancer, immunosuppression, chronic kidney disease, General Practice 
attendance rate in the year prior to cohort entry, and Accident and Emer-
gency attendance rate in the year prior to cohort entry
In the main analysis, we did not adjust for ethnicity as a sizable proportion 
of individuals with missing ethnicity (~23%). We undertook complete case 
analysis to address missing data
3. Repeated main analysis excluding people prescribed antiplatelets 
4 months before study start date
To explore the impact of use of antiplatelet which can reduce the risk of 
blood clots
4. Repeated main analysis excluding people who were prescribed both 
warfarin and DOACs on the day of the latest OAC prescription
To assess the sensitivity of exposure definition
5. Repeated main analysis excluding people who ever had warfarin pre-
scription 4 months before study start date in the DOAC group
As warfarin is hypothesised to have harmful effect on severe COVID-19 
compared with DOAC, this analysis was to assess the sensitivity of exposure 
definition
6. Time-updated the OAC exposure variable To evaluate the impact of national recommendation on drug switching 
from warfarin to DOACs due to COVID-19 pandemic [24]
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be associated with at least 1.7–1.85 times increased 
risk of unmeasured risk-prone behaviour or risk-
prone behaviour would need to be associated with 
1.7–1.85 times increased risk of each COVID-19 
outcome. Alternatively, both DOAC use and each 
COVID-19 outcome would need to be associated with 
the unmeasured risk-prone behaviour by associations 
ranging from 1.20 to 1.27 (Additional file 1: Table S7).
When we assumed an association between warfa-
rin and each COVID-19 outcome of 1.2 (i.e. a harm-
ful effect of warfarin compared with DOACs), either 
DOAC use would need to be associated with 2.25–2.41 
times higher risk of unmeasured risk-prone behav-
iour, or unmeasured risk-prone behaviour would need 
to be associated with 2.25–2.41 times higher risk of 
each outcome to potentially fully explain the observed 
inverse associations. Alternatively, both DOAC use 
and each outcome would need to be associated with 
the unmeasured risk-prone behaviour by associations 
ranging from 1.45 to 1.52.
Discussion
Principal findings
In this large cohort study of people with non-valvular 
AF, we observed a lower risk of developing SARS-CoV-2 
infection and hospital admission or death from COVID-
19 among warfarin users compared to those prescribed 
DOACs. Surprisingly, we also observed that warfarin 
users were less likely to be tested for SARS-CoV-2.
The protective associations seen for warfarin versus 
DOACs in all patients with AF are surprising given the 
hypothesis of a possible harm with warfarin and generally 
more comorbidities among warfarin users than DOAC 
users. Also, our findings were non-specific, including an 
inverse association with being tested for SARS-CoV-2, 
and death from non-COVID causes. This might be partly 
explained by the behavioural differences between war-
farin and DOAC users during COVID-19 pandemic. 
Although we cannot fully capture the behavioural dif-
ferences between exposure groups in the database, we 
observed that warfarin users are less likely to be current 
Fig. 2 Flow chart of inclusion of participants
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Table 2 Demographic and clinical characteristics
Current use of direct oral anticoagulant Current use of warfarin
Total 280,407 92,339
Age as of 1 Mar 2020
18– < 40 510 (0.2) 112 (0.1)
40– < 50 2320 (0.8) 361 (0.4)
50– < 60 12,788 (4.6) 2245 (2.4)
60– < 70 42,407 (15.1) 9824 (10.6)
70– < 80 98,848 (35.3) 34,051 (36.9)
80+ 123,534 (44.1) 45,746 (49.5)
Median, IQR 78 (71–84) 79 (73–85)
Sex
Female 122,778 (43.8) 36,414 (39.4)
Body mass index
 < 18.5 5437 (1.9) 1199 (1.3)
18.5–24.9 72,658 (25.9) 21,998 (23.8)
25–29.9 94,621 (33.7) 31,981 (34.6)
30–34.9 57,590 (20.5) 19,592 (21.2)
35–39.9 24,032 (8.6) 8114 (8.8)
40+ 12,586 (4.5) 4539 (4.9)
Missing 13,483 (4.8) 4916 (5.3)
Ethnicity
White 201,046 (71.7) 66,800 (72.3)
Mixed 548 (0.2) 115 (0.1)
Asian/Asian British 3911 (1.4) 766 (0.8)
Black 1289 (0.5) 258 (0.3)
Other 1100 (0.4) 281 (0.3)
Missing 72,513 (25.9) 24,119 (26.1)
Index of multiple deprivation
1 (least deprived) 57,570 (20.5) 17,703 (19.2)
2 56,881 (20.3) 18,400 (19.9)
3 55,654 (19.8) 19,056 (20.6)
4 54,758 (19.5) 18,615 (20.2)
5 (most deprived) 55,544 (19.8) 18,565 (20.1)
Smoking status
Never 101,492 (36.2) 33,005 (35.7)
Former 161,752 (57.7) 54,463 (59.0)
Current 16,828 (6.0) 4834 (5.2)
Missing 335 (0.1) 37 (0.0)
Hazardous alcohol use 28,375 (10.1) 7819 (8.5)
Care home residence 8133 (2.9) 1039 (1.1)
Comorbidities
Hypertension 195,078 (69.6) 66,888 (72.4)
Heart failure 71,427 (25.5) 26,926 (29.2)
Myocardial infarction 31,911 (11.4) 10,414 (11.3)
Peripheral arterial disease 14,273 (5.1) 5091 (5.5)
Stroke/transient ischaemic attack 60,271 (21.5) 18,470 (20.0)
Venous thromboembolism 19,927 (7.1) 8202 (8.9)
Diabetes
Controlled (HbA1c < 58 mmols/mol) 61,178 (21.8) 23,893 (25.9)
Uncontrolled (HbA1c ≥ 58 mmols/mol) 22,672 (8.1) 7696 (8.3)
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COPD, Chronic obstructive pulmonary disease
Table 2 (continued)
Current use of direct oral anticoagulant Current use of warfarin
HbA1c not measured 838 (0.3) 298 (0.3)
COPD 36,189 (12.9) 11,272 (12.2)
Other respiratory diseases 16,444 (5.9) 4731 (5.1)
Cancer 49,488 (17.6) 16,240 (17.6)
Immunosuppression 1688 (0.6) 528 (0.6)
Chronic kidney disease 95,715 (34.1) 34,633 (37.5)
Primary care consultations
Median, IQR 10 (6–17) 16 (9–27)
Min, Max 0, 432 0, 307
A&E attendance
Median, IQR 0 (0–1) 0 (0–1)
Min, Max 0, 69 0, 45
Flu vaccination 220,153 (78.5) 78,558 (85.1)
Medications
Oestrogen/oestrogen-like drugs 1652 (0.6) 361 (0.4)
Antiplatelets 19,030 (6.8) 4108 (4.4)
Fig. 3 Hazard ratios of the association between current use of warfarin and COVID-19-related outcomes and non-COVID-19 deaths, versus direct 
oral anticoagulants in people with non-valvular atrial fibrillation
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smokers, had less hazardous alcohol use and more likely 
to have had flu vaccination than DOAC users, but the dif-
ferences were small. Importantly, we adjusted for a range 
of confounders that had minimal impact to the esti-
mates. We further performed quantitative bias analyses 
and found that an unmeasured risk-averse behaviour of 
moderate strength could potentially explain the observed 
inverse associations. Further studies that can account for 
behavioural differences between groups are required to 
confirm the findings as we cannot rule this out as a pos-
sible contributor to our findings.
Although we did not anticipate there was a difference in 
non-COVID-19 mortality between warfarin and DOACs, 
others have also observed a similar association using 
another UK primary care data set [13]. We therefore tried 
to explore non-COVID deaths further to understand 
whether this finding was driven by a possibly superior 
therapeutic effect of warfarin, but there were too few 
outcomes to draw conclusions. Whilst the aetiology of 
the protective association we observed between warfarin 
and COVID-19-related outcomes is unclear, importantly 
our results do not suggest that warfarin is associated with 
COVID-19-related harm compared with DOACs.
Findings in context
Some early studies reported that elevated circulat-
ing D-dimer levels and prolonged prothrombin time 
were associated with mortality in people with COVID-
19 disease [14, 15], suggesting COVID-19 coagulopa-
thy [16]. The exact mechanism of hypercoagulability 
in COVID-19 disease is still not fully understood [17]. 
Therefore, anticoagulants have been proposed to be one 
of the investigational therapies in the management of 
COVID-19 disease, but the role of oral anticoagulants in 
severe COVID-19 outcomes remains unclear [18]. Fur-
ther, effects of different types of oral anticoagulants in 
COVID-19 outcomes might be different due to the dif-
ference in mechanisms of action. Desphospho-uncar-
boxylated matrix Gla protein (dp-ucMGP) is an indirect 
marker of extrahepatic vitamin K status where high dp-
ucMGP levels indicate low extrahepatic vitamin K status 
[19]. In a study of 135 hospitalised COVID-19 patients 
and 184 historical controls, it shows that dp-ucMGP 
was elevated in patients with COVID-19 compared with 
controls [3]. An even higher dp-ucMGP was observed 
in patients requiring intubation and mechanical ventila-
tion or all-cause death. However, this study was of small 
sample size which required larger studies to confirm the 
association. In particular, the number of regular vitamin 
K antagonist users was very small (n = 15) to elucidate 
any role of vitamin K antagonists in severe COVID-19 
outcomes. Another three cohort studies showed a trend 
of a lower risk of all-cause mortality associated with 
either prior use of warfarin or DOACs versus non-use of 
anticoagulants in patients with COVID-19 disease [4, 5, 
7]. Another German cohort study reported no evidence 
of an association between DOACs and severe COVID-19 
outcomes without including warfarin users into the anal-
ysis in people with non-valvular AF [6]. Notably, none of 
these studies directly compared the effects of warfarin 
with DOACs on COVID-19-related outcomes.
Strengths and limitations
The greatest strength of this study was the power ena-
bling us to examine the association between warfarin 
and various COVID-19-related outcomes versus DOACs 
as our data set included medical records from 24 million 
individuals. To our knowledge, this is the first population-
based study comparing both the risk of COVID-related 
outcomes and cause-specific deaths between warfarin 
and DOACs. We also conducted quantitative bias analy-
ses to explore the impact of unmeasured confounding to 
our observed results. The breadth of data available in pri-
mary care allows us to account for a wide range of poten-
tial confounders.
We recognise possible limitations. First, we could not 
eliminate residual confounding. Whilst differences in 
health behaviours and shielding between groups may 
partly explain our results, more studies are required to 
confirm these findings. Second, we are not able to cap-
ture any anticoagulant use during hospitalisation. Low 
molecular weight heparin or unfractionated heparin 
might be given for both warfarin and DOAC users with 
severe COVID-19 disease during hospitalisation to pre-
vent venous thromboembolism. As the use of heparin 
during hospitalisation between warfarin and DOACs 
users is unlikely to be differential, this would merely lead 
to an underestimation of the effect without account-
ing for the anticoagulation use during hospitalisation in 
the analysis. Therefore, a lack of data on heparin during 
hospitalisation would not affect our interpretation that 
there is no evidence of harmful effects of warfarin on 
COVID-19 outcomes. Third, we do not know whether 
patients took the medications as prescribed. However, if 
there is a non-differential misclassification bias of expo-
sure between warfarin and DOAC users, the estimates 
would be biased towards null. If DOAC users were more 
likely to adhere to their medication than warfarin users, 
the estimates would again tend to be biased towards null, 
with a hypothesis that warfarin has a harmful effect on 
COVID-19 outcomes. Moreover, we do not have data 
on inflammatory parameters to further explore the 
specific mechanism of severe COVID-19 disease due 
to coagulopathy in our cohort. It is recommended to 
incorporate inflammatory parameters into the outcome 
definition, so as to specifically investigate the impact of 
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oral anticoagulants in severe COVID-19 diseases due 
to coagulopathy in future research. Lastly, we adjusted 
for the use of oestrogen and antiplatelets in our analysis 
that are both potentially associated with the oral antico-
agulant type being prescribed and COVID-19 outcomes. 
However, we did not rule out the possibility of residual 
confounding due to other drug combinations with oral 
anticoagulants that were not adjusted for.
Conclusions
We found no evidence of a higher risk of severe COVID-
19 outcomes associated with warfarin versus DOACs, 
providing reassurance about the safety of warfarin use 
among patients with indications for anticoagulation 
in the context of the COVID-19 pandemic. We do not 
recommend changes to ongoing anticoagulant therapy 
based on these results.
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